Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer.
Clin Colorectal CancerApr 23, 2026 (epub)
Clinical ResearchOncology (Medical)
Lisa Salvatore, Marwan Fakih, Yasutoshi Kuboki et al.
✦ AI-curated · Sources linked
In 30 seconds
This study conducted a matching-adjusted indirect comparison to evaluate the efficacy of sotorasib plus panitumumab (soto960+pani) versus trifluridine/tipiracil plus bevacizumab (T/T+bev) in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The analysis revealed that soto960+pani significantly improved overall survival (OS) with a hazard ratio of 0.44 (95% CI, 0.22-0.87).
Key findings
- Soto960+pani had an adjusted odds ratio of 5.7 (95% CI, 2.6-12.8) for treatment response compared to T/T+bev.
- The hazard ratio for progression-free survival (PFS) was 0.77 (95% CI, 0.47-1.25) for soto960+pani.
- Soto960+pani demonstrated a hazard ratio for overall survival (OS) of 0.44 (95% CI, 0.22-0.87).
- Grade ≥ 3 adverse events occurred in 58% of soto960+pani patients versus 72% in T/T+bev patients.
Why it matters
The findings suggest that sotorasib plus panitumumab may offer a more effective treatment option for patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer, potentially leading to improved survival outcomes.